NCX 1004

Drug Profile

NCX 1004

Latest Information Update: 31 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NicOx
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Inflammatory bowel diseases

Most Recent Events

  • 27 Jul 2012 Discontinued - Preclinical for Asthma in Europe (unspecified route)
  • 27 Jul 2012 Discontinued - Preclinical for Inflammatory bowel disease in Europe (unspecified route)
  • 06 Nov 1998 Preclinical development for Asthma in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top